Our top pick for
Urovant Sciences Ltd is a biotechnology business based in the US. Urovant Sciences shares (UROV) are listed on the NASDAQ and all prices are listed in US Dollars. Urovant Sciences employs 70 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$7.15 - $16.26|
|50-day moving average||$16.21|
|200-day moving average||$13.98|
|Wall St. target price||$16.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.92|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-75.13%|
|Return on equity TTM||0%|
|Market capitalisation||$531.8 million|
TTM: trailing 12 months
There are currently 130,651 Urovant Sciences shares held short by investors – that's known as Urovant Sciences's "short interest". This figure is 67.3% up from 78,104 last month.
There are a few different ways that this level of interest in shorting Urovant Sciences shares can be evaluated.
Urovant Sciences's "short interest ratio" (SIR) is the quantity of Urovant Sciences shares currently shorted divided by the average quantity of Urovant Sciences shares traded daily (recently around 59657.99086758). Urovant Sciences's SIR currently stands at 2.19. In other words for every 100,000 Urovant Sciences shares traded daily on the market, roughly 2190 shares are currently held short.
However Urovant Sciences's short interest can also be evaluated against the total number of Urovant Sciences shares, or, against the total number of tradable Urovant Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Urovant Sciences's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Urovant Sciences shares in existence, roughly 0 shares are currently held short) or 0.0134% of the tradable shares (for every 100,000 tradable Urovant Sciences shares, roughly 13 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Urovant Sciences.
Find out more about how you can short Urovant Sciences stock.
We're not expecting Urovant Sciences to pay a dividend over the next 12 months.
Over the last 12 months, Urovant Sciences's shares have ranged in value from as little as $7.15 up to $16.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Urovant Sciences's is 2.3354. This would suggest that Urovant Sciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Urovant Sciences Ltd. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017.
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.